ANP

What is ANP?

Atrial natriuretic peptide (ANP) is a 28-amino-acid endogenous peptide hormone with a characteristic 17-residue disulfide ring (Cys7–Cys23) that defines the natriuretic peptide family. It is synthesized in atrial cardiomyocytes as a 151-amino-acid preprohormone (preproANP), processed to the 126-residue proANP storage form held in dense atrial granules, and released into the circulation upon atrial stretch — the molecular signal of intravascular volume expansion or rising filling pressures. The active 28-aa C-terminal fragment circulates as the mature hormone, while the inactive N-terminal fragment (NT-proANP) is co-secreted in equimolar amounts and used clinically as a more stable plasma biomarker. ANP signals primarily through natriuretic peptide receptor A (NPR-A, also called GC-A or NPR1), a membrane-bound guanylyl cyclase that generates intracellular cyclic GMP and drives natriuresis, vasodilation, plasma volume reduction, and suppression of the renin-angiotensin-aldosterone axis. As a therapeutic, native human ANP was developed in Japan as carperitide (α-human ANP — the full 28-amino-acid peptide, brand name Hanp) and approved in Japan in 1995, under what was then the Ministry of Health and Welfare, for acute decompensated heart failure (ADHF). Carperitide should not be confused with anaritide, a different molecule: anaritide is a truncated 25-amino-acid ANP analogue developed in the United States and trialled for acute tubular necrosis, and it was never approved anywhere. It has remained a country-specific therapy, in widespread Japanese hospital use as an intravenous infusion for ADHF and after cardiac surgery. Carperitide was never FDA-approved in the United States; the structurally related recombinant human BNP, nesiritide, was FDA-approved in 2001 for ADHF but was largely withdrawn from clinical favor after the ASCEND-HF trial showed no survival benefit, leaving the natriuretic peptide therapeutic class effectively absent from current US heart failure practice. ANP itself remains foundational to cardiovascular physiology and underlies all natriuretic peptide pharmacology, including the neprilysin-inhibitor mechanism of sacubitril/valsartan (Entresto).

What ANP Is Investigated For

ANP is best understood as the prototype natriuretic peptide — the molecule whose discovery in 1981 by de Bold and colleagues opened the field and reframed the heart as an endocrine organ. Its physiological role as a counter-regulator to the renin-angiotensin-aldosterone system is uncontested and reproduced across decades of human and animal studies. As a drug, however, ANP has had a narrow trajectory. Recombinant human ANP (carperitide) reached the Japanese market in 1995 for acute decompensated heart failure on the strength of short-term hemodynamic benefits — pulmonary capillary wedge pressure reduction, increased natriuresis, decreased systemic vascular resistance — but the global heart failure community has been more cautious: the propensity-matched evidence is genuinely split. Matsue and colleagues (2015) found carperitide associated with roughly double the in-hospital mortality (OR 2.13, 95% CI 1.17–3.85), while Ogiso and colleagues (2017), using the same propensity-matched design, found no significant difference at all (4.0% versus 5.1%, p=0.609). A 2025 systematic review and meta-analysis of 30,665 patients resolved the question in the direction of modest harm: in-hospital mortality was significantly higher with carperitide (RR 1.16, 95% CI 1.07–1.27), with no difference in heart-failure-related mortality (RR 0.81, 95% CI 0.45–1.45). Contemporary Japanese heart failure guidelines now position carperitide more conservatively than they once did. Outside Japan, ANP itself was never marketed; nesiritide, which is recombinant human BNP rather than an analogue, reached the US market but lost favor after ASCEND-HF and has since been discontinued. Today, the most clinically impactful translation of ANP biology is indirect: sacubitril/valsartan (Entresto), an angiotensin receptor / neprilysin inhibitor, leverages neprilysin blockade to raise endogenous ANP and BNP levels and is a guideline-directed cornerstone therapy for HFrEF following PARADIGM-HF. ANP-based diagnostic biomarkers (plasma ANP, NT-proANP, MR-proANP) are used in some research and European clinical contexts, but BNP and NT-proBNP dominate routine US heart-failure laboratory practice because of better assay stability and longer half-lives.

History & Discovery

ANP's history began with a now-iconic morphological observation. In the 1950s and 1960s, electron microscopists noted that mammalian atrial cardiomyocytes — but not ventricular cardiomyocytes — contained dense, membrane-bound secretory granules resembling those of endocrine cells. The morphology hinted at a hormonal function for the atria, but no candidate hormone was identified for two decades. The breakthrough came from a collaboration led by Adolfo J. de Bold, then at Queen's University in Kingston, Ontario. In a short paper published in Life Sciences in January 1981, de Bold, Borenstein, Veress, and Sonnenberg reported that intravenous injection of crude rat atrial myocardial extract produced a 'rapid and potent natriuretic response' in anesthetized rats — an immediate and dramatic rise in urinary sodium excretion — while ventricular extract produced no such effect. The simplicity of the experiment and the magnitude of the response made the result immediately compelling. The de Bold paper effectively founded the natriuretic peptide field, reframed the heart as a bona fide endocrine organ, and triggered an international race to isolate and characterize the responsible factor. Within three years, several laboratories had purified and sequenced the active peptide. Flynn et al. (1983) in Canada, Currie, Geller, Cole and colleagues at Washington University and Monsanto (Science 1984), Napier and colleagues at Merck (BBRC 1984), and Kangawa and Matsuo in Japan (1984) independently reported the structural characterization of atrial peptides — variously called atriopeptins, cardionatrin, and atrial natriuretic factor (ANF) — converging on the 28-amino-acid mature human peptide with its characteristic 17-residue disulfide ring. The gene (NPPA) was cloned shortly thereafter, and by the late 1980s the broader natriuretic peptide family — BNP (Sudoh, Kangawa, Matsuo 1988) and CNP (Sudoh 1990) — had been identified, along with the receptor architecture (Chinkers, Garbers et al., Nature 1989) showing NPR-A to be a membrane-bound guanylyl cyclase. The physiological framework was filled in through the 1980s and 1990s: human infusion studies (Cody et al., J Clin Invest 1986; Richards, Nicholls and colleagues in New Zealand) established the natriuretic, vasodilatory, and RAAS-suppressive actions of ANP in normal subjects and heart failure patients; ANP and NPR-A gene knockouts (John, Krege, Smithies et al., Science 1995; Lopez 1995) confirmed the peptide's central role in salt-sensitive blood pressure regulation; and biomarker assays for ANP, NT-proANP, and especially BNP and NT-proBNP became clinical standards for heart failure diagnosis and prognosis. The therapeutic translation took different paths in different countries. In Japan, recombinant human ANP — carperitide — was developed by Suntory and approved by the Japanese regulatory authority in 1995 for acute decompensated heart failure on the strength of short-term hemodynamic data. It became and remains a widely used Japanese hospital therapy, though propensity-matched analyses through the 2010s (Matsue 2015, Ogiso 2017) have raised an unresolved mortality signal that has tempered enthusiasm. In the United States, native ANP was never marketed; the related BNP analog nesiritide was FDA-approved in 2001 for acute decompensated heart failure but was largely abandoned after the ASCEND-HF trial (O'Connor 2011) showed no mortality benefit. Internationally, the most successful translation of natriuretic peptide biology has been indirect: the angiotensin receptor / neprilysin inhibitor sacubitril/valsartan (Entresto), validated in PARADIGM-HF (McMurray 2014), boosts endogenous ANP and BNP tone and is now a guideline-directed cornerstone therapy for HFrEF — an outcome that retroactively vindicated four decades of de Bold-era physiology.

How It Works

When the heart's atria stretch — a sign that the body has too much fluid or pressure — the atrial muscle cells release ANP into the bloodstream. ANP travels to the kidneys and blood vessels, where it tells the kidneys to dump sodium and water into the urine and tells blood vessels to relax. It also tells the body to slow down two of its main fluid-retaining hormones, renin and aldosterone. The net effect is to lower blood volume and blood pressure — essentially the heart's way of saying 'we're overloaded, please offload.'

ANP is the prototype member of the natriuretic peptide family — alongside BNP (B-type natriuretic peptide), CNP (C-type natriuretic peptide), and the structurally distinct guanylin-family peptides. It is encoded by the NPPA gene on chromosome 1p36, expressed predominantly in atrial cardiomyocytes, and synthesized as a 151-amino-acid preprohormone (preproANP) that is cleaved to the 126-aa proANP and stored in atrial-specific dense granules. Upon atrial stretch — the molecular consequence of intravascular volume expansion or rising atrial pressure — the cell-surface protease corin cleaves proANP to release the bioactive 28-amino-acid C-terminal fragment (mature ANP, residues 99–126) into the circulation, along with the inactive 98-amino-acid N-terminal fragment (NT-proANP). The 17-residue intramolecular disulfide ring (Cys7–Cys23) is the conserved structural signature of all natriuretic peptides and is required for receptor binding. ANP signals primarily through natriuretic peptide receptor A (NPR-A; also designated GC-A, NPR1, or guanylyl cyclase A), a single-pass membrane receptor with an intrinsic intracellular guanylyl cyclase domain. Binding of ANP to the extracellular ligand-binding domain triggers receptor dimerization, ATP-dependent conformational rearrangement of the intracellular kinase-homology domain, and activation of the cytosolic guanylyl cyclase catalytic domain — generating cyclic GMP from GTP. cGMP then activates protein kinase G (PKG), modulates cyclic-nucleotide-gated ion channels, and is hydrolyzed by cGMP-specific phosphodiesterases (notably PDE5 and PDE9). A second receptor, NPR-C (NPR3, the natriuretic peptide clearance receptor), binds all three natriuretic peptides with high affinity but lacks a guanylyl cyclase domain; it functions primarily as a clearance receptor that internalizes and degrades the bound peptide, with secondary inhibitory G-protein signaling. The physiological actions of ANP fall into four major categories. (1) Renal: ANP increases glomerular filtration rate by dilating afferent arterioles and constricting efferent arterioles, raising glomerular hydrostatic pressure; it inhibits sodium reabsorption in the inner medullary collecting duct (the most ANP-sensitive nephron segment) by closing apical ENaC sodium channels via cGMP-PKG signaling; and it antagonizes vasopressin-mediated water reabsorption. The net renal effect is a brisk natriuresis and diuresis. (2) Vascular: ANP relaxes vascular smooth muscle through cGMP-PKG, producing both arteriolar and venous dilation, lowering systemic vascular resistance, preload, and afterload. (3) Endocrine: ANP suppresses renin release from the juxtaglomerular apparatus, suppresses aldosterone synthesis in the adrenal zona glomerulosa, and reduces vasopressin and endothelin secretion — effectively counter-regulating the entire renin-angiotensin-aldosterone-vasopressin axis. (4) Cardiac and growth: ANP exerts anti-hypertrophic and anti-fibrotic effects on cardiomyocytes and fibroblasts, modulating cardiac remodeling in long-term overload states. Clearance of ANP is rapid and occurs through three parallel routes: (a) NPR-C-mediated receptor internalization and lysosomal degradation; (b) proteolytic degradation by neprilysin (neutral endopeptidase, NEP, EC 3.4.24.11), a ubiquitous membrane peptidase abundantly expressed on renal proximal tubule, vascular endothelium, and lung; and (c) renal filtration and proximal-tubule degradation. The plasma half-life of mature ANP is only 2–5 minutes, much shorter than BNP (~20 minutes) or NT-proBNP (~120 minutes) — which is why BNP and NT-proBNP, not ANP, dominate routine clinical biomarker use. Therapeutically, the neprilysin pathway has been the most successful pharmacological lever: sacubitril, the neprilysin-inhibitor prodrug component of sacubitril/valsartan (Entresto), raises endogenous ANP and BNP tone and underpins the drug's HFrEF mortality benefit established in PARADIGM-HF.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about ANP:

• 01No adequately powered randomized trial has tested whether carperitide infusion in acute decompensated heart failure improves mortality or heart failure rehospitalization. The observational record is mixed — harm in Matsue 2015, null in Ogiso 2017, and a modest pooled excess in-hospital mortality (RR 1.16) in a 2025 meta-analysis of 30,665 patients. The largest randomized evidence for intravenous hANP comes from a different setting: J-WIND (Lancet 2007) randomized 569 acute-MI patients to hANP or placebo and found a 14.7% reduction in infarct size (CK ratio 0.85, 95% CI 0.75–0.97, p=0.016) plus a small ejection-fraction gain at 6–12 months — but that result has never been reproduced outside Japan or extended to decompensated heart failure, and 29 of the hANP patients developed severe hypotension versus one on placebo.
• 02Optimal patient selection for natriuretic peptide infusion therapy — biomarker-guided, hemodynamic-guided, or clinical phenotype-guided — is not standardized.
• 03Whether ANP-based biomarkers (NT-proANP, MR-proANP) add incremental clinical value over BNP and NT-proBNP in heart failure diagnosis and risk stratification has been studied but not definitively answered.
• 04The role of ANP and natriuretic peptide signaling in atrial fibrillation pathogenesis is biologically plausible but mechanistically unresolved — although 2026 clinical work (Oka et al., Circ Rep 2026) has begun to position a low ANP/BNP ratio as a surrogate marker of advanced atrial remodeling and post-ablation recurrence risk, and Kobayashi et al. (Neurol Sci 2026) reported high AUC for ANP in predicting occult AF in embolic stroke of undetermined source.
• 05Long-acting natriuretic peptide analogs and small-molecule NPR-A agonists have been pursued for decades without an approval, but the pipeline is not empty. The most advanced candidate is MANP (M-atrial natriuretic peptide), a designer ANP analogue that activates GC-A: a first-in-human study (Hypertension 2021) and a 22-patient proof-of-concept trial in hypertension with metabolic syndrome showed that a single subcutaneous dose was safe and well tolerated and lowered blood pressure while also producing lipolytic and insulin-sensitising effects. A 120-patient Phase 2 trial of once-daily subcutaneous MANP for 42 days in difficult-to-control hypertension (NCT06343298, E-Star BioTech) began in November 2024 and is recruiting, with estimated primary completion in July 2027. Cenderitide, ANX042 and CRRL269 are earlier-stage designer peptides in the same programme. Whether any of them clears Phase 3 is unresolved.
• 06Whether ANP-amyloid — isolated atrial amyloidosis, in which ANP itself misfolds and deposits in atrial tissue — is a cause or a consequence of atrial fibrillation. A 2026 echocardiographic-histopathologic study found such deposition in 51.2% of a surgical cohort, with left atrial reservoir strain declining progressively across amyloid grades, but the direction of causality is unresolved and the condition is absent from most clinical discussion of ANP.
• 07Whether the heart-to-adrenal axis can be drugged. ANP suppresses aldosterone, and 2026 in-vivo work indicates that ANP-mediated heart-adrenal communication moderates zona glomerulosa growth and aldosterone release, with impaired ANP/cGMP signalling driving excessive growth and aldosterone production — raising the untested question of whether this arm could be targeted in primary aldosteronism or resistant hypertension.
• 08Tissue-specific roles of ANP in metabolism, lipolysis, and adipocyte browning have been described preclinically and in small human studies but have not translated to therapeutic use.
• 09Whether perioperative carperitide reduces acute kidney injury and improves cardiac surgical outcomes — a Japanese-driven research focus — has been studied in small trials with mixed results and lacks definitive multinational data.

Forms & Administration

ANP itself is not available as a therapeutic in the United States. In Japan, recombinant human ANP is marketed as carperitide (brand name Hanp) for intravenous administration in acute decompensated heart failure. Carperitide is supplied as a lyophilized powder for reconstitution and is given as a continuous IV infusion typically starting at 0.05–0.1 mcg/kg/min and titrated to hemodynamic response (commonly to a maximum of around 0.2 mcg/kg/min) under inpatient cardiac monitoring. The infusion is short-term (hours to a few days) and requires close blood pressure, renal function, and electrolyte monitoring. Plasma ANP and NT-proANP / MR-proANP are also measurable in research and some clinical laboratories as biomarkers — assayed from EDTA plasma — though most US clinical labs use BNP or NT-proBNP instead because of better assay stability and longer half-lives. A separate molecule, the truncated 25-amino-acid analogue anaritide, was infused intravenously at 0.2 mcg/kg/min in US trials of acute tubular necrosis during the 1990s; it never reached market, and development stopped after a confirmatory trial failed to reproduce the one favourable subgroup. There is no oral, subcutaneous, or outpatient form of native ANP; the peptide's 2–5 minute plasma half-life makes any non-IV administration mechanistically impractical.

Common Questions

Who ANP Is NOT For

Drug & Supplement Interactions

ANP and carperitide are eliminated by neprilysin-mediated proteolysis, NPR-C-mediated clearance, and renal filtration, with no meaningful hepatic cytochrome P450 metabolism — so classical pharmacokinetic CYP-based drug interactions are not expected. The dominant interactions are pharmacodynamic. Vasodilators and antihypertensives (ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, organic nitrates, hydralazine, alpha-blockers) produce additive hypotension when combined with carperitide infusion and require careful titration. Diuretics (loop, thiazide, potassium-sparing) produce additive natriuresis and can precipitate hypovolemia, electrolyte disturbance, and reflex neurohormonal activation; close volume status and electrolyte monitoring is mandatory during co-administration. Neprilysin inhibitors (sacubitril, the active component of sacubitril/valsartan / Entresto) raise endogenous ANP and BNP levels by blocking their proteolytic clearance, and therefore amplify natriuretic peptide signaling. Combining a neprilysin inhibitor with exogenous carperitide infusion would be expected to produce additive effects and is not standard clinical practice; the two strategies represent alternative routes to the same physiological endpoint. Sacubitril/valsartan is contraindicated within 36 hours of ACE inhibitor use (because of angioedema risk from combined ACE and neprilysin inhibition affecting bradykinin metabolism), and similar caution applies to neprilysin-inhibitor / ANP combinations. Sympathomimetics, NSAIDs (which blunt natriuretic peptide effects via prostaglandin pathway interference), and corticosteroids (which raise ANP and ventricular natriuretic peptide expression) all have the potential for clinically meaningful pharmacodynamic interactions in volume-overloaded patients. As always, the operative reference for specific dose adjustment and interaction guidance is the institutional protocol and the current carperitide prescribing information in the relevant jurisdiction (Japanese label for carperitide), not this summary.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions